Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027

  • ID: 4316245
  • Report
  • Region: Global
  • 425 Pages
  • Roots Analysis
10 % OFF
until May 20th 2018
1 of 5

FEATURED COMPANIES

  • 23andMe
  • Cell Genetics
  • Genetadi Biotech
  • K3
  • NIPD Genetics
  • SeraCare Life Sciences
  • MORE

It has been estimated that close to 131 million babies are born each year across the globe. Of these, approximately 7.9 million are born with birth defects. In fact, more than 7,000 genetic disorders have been identified so far and the number is rising.Genetic testing solutions that enable early detection of genetic abnormalities in fetuses and newborns are important to ensure that the person does not face complications later in life. With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing have become popular. These include carrier testing, preimplantation genetic diagnosis/screening (PGD/PGS), prenatal testing, paternity testing and newborn screening. Amongst these, prenatal testing (primarily Non-invasive prenatal testing (NIPT)) and newborn screening have gained relatively more traction in prenatal and neonatal care.

Specifically, NIPT has emerged as an efficient screening method in prenatal care that can analyze the cell-free DNA (cfDNA) extracted from maternal blood sample during pregnancy. NIPTs offer several advantages over conventional prenatal testing procedures; in addition to being non-invasive, these tests offer shorter turnaround times and high accuracy. It has been reported that the increasing popularity of NIPTs has led to a 50% decline in the use of invasive prenatal testing procedures (such as amniocentesis and chorionic villus sampling (CVS)). With the changing mindset of people belonging to different cultural and socio-economic background, the uptake of NIPTs is likely to increase further. Moreover, with the rising awareness and availability of NIPTs designed for a wide array of disease indications, and development of innovative and versatile technologies, we expect that the interest will continue to grow.

Within neonatal care, the emergence of advanced technologies in this domain has reflected a gradual rise in the overall development of advanced newborn screening tests in the last few years. In fact, public service bodies in more than 70 countries across the globe have facilitated the establishment of newborn screening programs in their respective countries. With an already established platform, we expect the overall newborn screening market to continue its gradual rise driven by higher adoption, competitive prices and availability of these tests in various geographies across the globe.

The "Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027" report features an extensive study on the current market landscape of non-invasive prenatal testing (NIPT) and newborn screening diagnostics that are commercially available or are under development. NIPT and newborn screening tests are designed for the detection of different types of genetic abnormalities in fetuses and newborns. Detection of genetic disorders in prenatal and neonatal stages is critical tolower the child mortality rates. Moreover, early detection, treatment and management of these genetic disorders is important to avoid serious health problems at later stages in life. The study offers a comprehensive discussion on the future potential of these tests in prenatal and neonatal care.
 
Ever since the launch and subsequent success of the first NIPT, the NIFTY® test (launched by BGI in August 2011), several firms have taken initiatives to develop and commercialize NIPTs. Currently, a number of NIPTs that are designed to screen for conditions such as chromosomal abnormalities, sex chromosomal abnormalities and microdeletion syndromes are available in the market.In addition, many companies have entered into collaborations to distribute these tests across various geographies in order to expand the availability to a wider population. Examples of popular NIPT tests include Harmony® test (Ariosa Diagnostics, acquired by Roche), PraenaTest®/PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Panorama® (Natera®), NIFTY® (BGI), Verifi® (Verinata Health, acquired by Illumina®), VisibiliTTM (SequenomTM, acquired by LabCorp®) and IONA® test/Safe NIPT (Premaitha Health).
 
The advent of routine newborn screening in the 1960s for the detection of phenylketonuria (PKU) established the role and importance of newborn screening in mitigating disorders in newborns. The field is continuously evolving as the awareness related to benefits of newborn screening increases. Moreover, introduction of advanced technologies such as next-generation sequencing (NGS) and tandem mass spectroscopy has notably accelerated the development in this domain. Newborn screening diagnostics are primarily available for conditions such as metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders.
 
Both prenatal testing and newborn screening offer several benefits in terms of disease management in neonatal care and has gathered interest from a wide range of companies worldwide. In total, we have identified 76 NIPT tests and 38 advanced newborn screening tests. In addition, there are several companies that are engaged in the development of basic tests, devices, systems and technology platforms for both prenatal testing and newborn screening. One of the key objectives of this report was to understand the current activity and the future potential of the NIPT and newborn screening markets. Amongst other elements, the report covers the following:

NIPT:

  • The overall landscape of NIPT tests with respect to the stage of development, sample type, technology platforms, type of indications, stage of pregnancy and result turnaround time. In addition, the report provides a detailed discussion and analysis on the various innovative technology platforms available for the development of NIPTs and the indications screened.
  • Comprehensive profiles of the leading players in the field of NIPT and their products, highlighting details of the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product and their development history, technology platforms, test procedure, specifications, advantages and clinical information (if available).
  • An elaborate geographical coverage analysis of the NIPT tests available/under development across the globe, a comparative heat map analysis of NIPTs (on the basis of sensitivity, specificity, result turnaround time and stage of pregnancy when the test can be performed), harvey ball analysis highlighting the panel strength of each test based on the number of indications being screened, and the geographical distribution of the companies involved in the development of NIPTs.

Newborn Screening:

  • The overall landscape of newborn screening tests with respect to the stage of development, screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time.
  • Detailed profiles of the players involved in the field of newborn screening and their products highlighting details on the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product specifications and test methodology. In addition, the report includes a comprehensive list of the core and secondary disorders/deficiencies recommended for newborn screening.
  • An illustrative grid representation of the newborn screening tests based on screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and technology platform, and an overview of the landscape of industry developers (start-ups, mid-sized and large-sized players).

Additionally, the report includes:

  • A detailed discussion of the existing regulatory landscape in the field of NIPT and the current status of the government mandated newborn screening programs established in various countries across the globe to provide proper medical care to newborns.
  • Partnerships that have been recently been inked amongst different stakeholders, covering product distribution/marketing agreements, development/commercialization agreements and mergers/acquisitions.
  • A detailed survey analysis primarily focused on gaining additional insights on the company’s tests or services, highlighting the focus area of the company, type of the products, purpose and commercial availability of the lead product(s).

Example Highlights

  1. During our research, we identified 76 NIPTs; of the commercially available tests, majority are laboratory-developed tests while only a few are CE-IVD certified. The CE-IVD marked tests include Clarigo® (Multiplicom), Harmony® test (Ariosa Diagnostics, acquired by Roche), IONA® test (Premaitha Health), Prenatal BACs-on-BeadsTM (PerkinElmer®), PraenaTest®/PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Prendia (Genesupport, FASTERIS, Swiss Institute for Bioinformatics), SerenityTM test (Genesis GeneticsTM) and Tranquility (Genoma, a subsidiary of ESPERITE).
  2. Of the total NIPTs (commercially available/under development), 83% are designed on the basis of massively parallel sequencing/next-generation sequencing methods (MPS/NGS) for the detection of diseases under their test panels. It is worth highlighting that some developers are utilizing a novel epigenetics based approach for the development of their NIPTs.
  3. The current market landscape features contributions from big pharmaceutical companies and small to mid-sized players. Established players engaged in the development of NIPTsinclude (in alphabetical order) BGI, Natera®, PerkinElmer®, SequenomTM (acquired by LabCorp®), Sonic Healthcare and Quest DiagnosticsTM. Small and mid-sized companies engaged in the field of NIPT include (in alphabetical order) Ariosa Diagnostics (acquired by Roche), Berry Genomics, EvolveGene, LifeCodexx (a subsidiary of GATC Biotech), NIPD Genetics, NxGen MDx, Premaitha Health and Verinata Health (acquired by Illumina®).
  4. Prominent academic institutions and universities involved in the field of NIPT include (in alphabetical order) the Birmingham Women’s Hospital, Cyprus Institute of Neurology and Genetics, Murdoch Children’s Research Institute, National University of Singapore, Stanford University, Swiss Institute for Bioinformatics, The Chinese University ofHong Kong and University of Antwerp.
  5. We also came across 38 advanced newborn screening tests available for the detection of a large number of disorders/deficiencies including metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders. Of the total advanced newborn screening tests, 66% of the tests use blood as the testing sample (categorized as basic screening tests). This is followed by advanced screening tests and comprehensive screening tests capturing a share of 16% and 10%, respectively. Nearly 8% of the newborn screening tests utilize urine as the sample and are categorized as expanded newborn screening tests.
  6. Over 135 collaborations have been inked in the field of NIPT between 2011 and 2017. Although a significant proportion of these agreements focus on distribution/marketing of NIPTs to expand their access and coverage in different geographies (54%), we came across a number of product development/commercialization agreements (15%), merger/acquisition agreements (9%) and product/technology licensing agreements (8%). Several companies have entered into multiple collaborations; these include SequenomTM (24 agreements), Natera® (20 agreements), Premaitha Health (19 agreements), BGI (18 agreements), Ariosa Diagnostics (14 agreements) and Illumina® (13 agreements).
  7. The NIPT market, primarily driven by increasing awareness and adoption of NIPTs, is anticipated to grow at an annualized rate of 15% between 2017 and 2027. The current market is dominated by the tests offered to expectant women belonging to high risk category, capturing 52% market share. However, by 2027, the average risk market is likely to be amongst the key drivers; we expect its share to grow from 37% in 2017 to 45% by 2027.
  8. Amongst specific indications screened under NIPT test panels, chromosomal abnormalities (primarily including trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome))are likely to capture the largest share of the market in both 2017 (44%) and 2027 (56%). This is followed by sex chromosomal abnormalities, capturing a share of 24% in 2017 and 28% in 2027. These include Turner syndrome, Klinefelter syndrome, Triple X syndrome and Jacob syndrome. Microdeletion syndromes, primarily including Cri-du-chat syndrome, DiGeorge syndrome, Prader-Willi syndrome, monosomy 1p36 and Wolf-Hirschhorn syndrome, are likely to account for a share of 22% in 2017 and 14% in 2027.
  9. With regard to the geographical activity, in 2017, the North America is likely to capture the maximum share (37%) followed by Europe (35%) and Asia (24%). Over the coming decade, Asian regions are likely to drive the growth resulting in a share of 29% in 2027. It is important to highlight that, within Asia, countries such as China, India, Japan, have several developers and distributors of NIPT tests, demonstrating an increasing interest in these regions.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 23andMe
  • Cell Genetics
  • Genetadi Biotech
  • K3
  • NIPD Genetics
  • SeraCare Life Sciences
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Importance of Disease Detection: Screening Versus Diagnosis
3.3. Genetic Abnormalities: An Introduction
3.3.1. Classification of Genetic Disorders
3.3.1.1. Chromosomal Abnormalities
3.3.1.2. Single Gene Disorders
3.3.1.3. Teratogenic Problems
3.3.1.4. Complex/Multifactorial Problems
3.3.2. Statistics and Epidemiology of Genetic Disorders
3.3.3. Common Genetic Disorders: Causes and Symptoms
3.4. Genetic Tests: Importance in Prenatal and Neonatal Care
3.5. Prenatal Genetic Testing: A Detailed Overview
3.5.1. Conventional Methods of Prenatal Testing
3.5.1.1. Maternal Serum Screening
3.5.1.2. Ultrasonography
3.5.1.3. Invasive Confirmatory Tests
3.5.1.3.1. Amniocentesis
3.5.1.3.2. Chorionic Villus Sampling (CVS)
3.5.1.4. Fetal Cells in Maternal Blood (FCMB)
3.5.2. Non-Invasive Prenatal Testing (NIPT)
3.6. The Concept of Newborn Screening
3.6.1. Evolution of Newborn Screening
3.7. Ethical Issues Related to Prenatal Testing and Newborn Screening
 
4. NIPT AND NEWBORN SCREENING: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. NIPT: Development Landscape
4.2.1. NIPT: Distribution by Stage of Development
4.2.2. NIPT: Distribution by Technology Platforms
4.2.3. NIPT: Distribution by Type of Indication
4.2.4. NIPT: Distribution by Stage of Pregnancy
4.2.5. NIPT: Distribution by Result Turnaround Time
4.3. NIPT: Technology Platforms
4.4. Prenatal Testing: Other Initiatives
4.5. Newborn Screening: Development Landscape
4.5.1. Newborn Screening: Distribution by Screening Type
4.5.2. Newborn Screening: Distribution by Technology Platforms
4.5.3. Newborn Screening: Distribution by Type of Indication
4.5.4. Newborn Screening: Distribution by Period of Sample Collection After Birth
4.5.5. Newborn Screening: Distribution by Result Turnaround Time
4.6. Newborn Screening: Other Initiatives
 
5. NIPT AND NEWBORN SCREENING: KEY INSIGHTS
5.1. Chapter Overview
5.2. NIPTs: Distribution by Geographical Coverage
5.3. Commercialized NIPTs: A Competitive Heat Map Analysis for Clinical Efficiency
5.4. NIPTs: Harvey Ball Analysis for Test Panel Strength
5.5. NIPTs: Geographical Distribution of Industry Players
5.6. Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
5.7. Newborn Screening Developer Landscape: Distribution by Company Size and Geography
 
6. PRENATAL TESTING: FOCUS ON NIPT
6.1. Chapter Overview
6.2. Emergence of NIPT
6.3. NIPT Key Players: Company Profiles
6.3.1. Ariosa Diagnostics (Acquired by Roche)
6.3.1.1. Company Introduction
6.3.1.2. Financial Information
6.3.1.3. Product Portfolio
6.3.1.3.1. Harmony® Test
6.3.1.3.1.1. Product Overview and Development History
6.3.1.3.1.2. Product Specifications
6.3.1.3.1.3. Technology Overview
6.3.1.3.1.4. Procedure and Interpretation of Results
6.3.1.3.1.5. Advantages
6.3.1.3.1.6. Clinical Information
6.3.1.4. Future Outlook
6.3.2. BGI
6.3.2.1. Company Introduction
6.3.2.2. Financial Information
6.3.2.3. Product Portfolio
6.3.2.3.1. NIFTY® Test
6.3.2.3.1.1. Product Overview and Development History
6.3.2.3.1.2. Product Specifications
6.3.2.3.1.3. Technology Overview
6.3.2.3.1.4. Procedure and Interpretation of Results
6.3.2.3.1.5. Advantages
6.3.2.3.1.6. Clinical Information
6.3.2.4. Future Outlook
6.3.3. Natera®
6.3.3.1. Company Introduction
6.3.3.2. Financial Information
6.3.3.3. Product Portfolio
6.3.3.3.1. Panorama® Test
6.3.3.3.1.1. Product Overview and Development History
6.3.3.3.1.2. Product Specifications
6.3.3.3.1.3. Technology Overview
6.3.3.3.1.4. Procedure and Interpretation of Results
6.3.3.3.1.5. Advantages
6.3.3.3.1.6. Clinical Information
6.3.3.4. Future Outlook
6.3.4. SequenomTM (Acquired by LabCorp®)
6.3.4.1. Company Introduction
6.3.4.2. Financial Information
6.3.4.3. Product Portfolio
6.3.4.3.1. MaterniT® GENOME
6.3.4.3.1.1. Product Overview and Development History
6.3.4.3.1.2. Product Specifications
6.3.4.3.1.3. Procedure and Interpretation of Results
6.3.4.3.1.4. Advantages
6.3.4.3.1.5. Clinical Information
6.3.4.3.2. VisibiliTTM Test
6.3.4.3.2.1. Product Overview and Development History
6.3.4.3.2.2. Product Specifications
6.3.4.3.2.3. Procedure and Interpretation of Results
6.3.4.3.2.4. Advantages
6.3.4.3.2.5. Clinical Information
6.3.4.3.3. MaterniT21® PLUS Test
6.3.4.3.3.1. Product Overview and Development History
6.3.4.3.3.2. Product Specifications
6.3.4.3.3.3. Technology Overview
6.3.4.3.3.4. Procedure and Interpretation of Results
6.3.4.3.3.5. Advantages
6.3.4.3.3.6. Clinical Information
6.3.4.3.4. SensiGene® RhD Test
6.3.4.3.4.1. Product Overview and Development History
6.3.4.3.4.2. Product Specifications
6.3.4.3.4.3. Technology Overview
6.3.4.3.4.4. Procedure and Interpretation of Results
6.3.4.3.4.5. Advantages
6.3.4.3.4.6. Clinical Information
6.3.4.3.5. NextViewTM Array Diagnostic Test Platform
6.3.4.3.5.1. Product Overview and Development History
6.3.4.3.5.2. Product Specifications
6.3.4.4. Future Outlook
6.3.5. Verinata Health (Acquired by Illumina®)
6.3.5.1. Company Introduction
6.3.5.2. Financial Information
6.3.5.3. Product Portfolio
6.3.5.3.1. Verifi® Prenatal Test/InformaSeqSM
6.3.5.3.1.1. Product Overview and Development History
6.3.5.3.1.2. Product Specifications
6.3.5.3.1.3. Technology Overview
6.3.5.3.1.4. Procedure and Interpretation of Results
6.3.5.3.1.5. Advantages
6.3.5.3.1.6. Clinical Information
6.3.5.4. Future Outlook
6.4. Popular NIPTs: A Detailed Comparison
6.5. NIPT: Regulatory Landscape
6.6. NIPT: Future Outlook
 
7. NEWBORN SCREENING: DETAILED OUTLOOK
7.1. Chapter Overview
7.2. Newborn Screening: Introduction and Classification
7.2.1. Classification of Newborn Screening Tests: By Sample Type
7.2.2. Classification of Newborn Screening Tests: By Period of Sample Collection After Birth
7.2.3. Classification of Newborn Screening: By Patient Risk Group
7.3. Technological Advances in Newborn Screening
7.4. Newborn Screening Key Players: Company Profiles
7.4.1. BGI
7.4.1.1. Company Introduction
7.4.1.2. Financial Information
7.4.1.3. Product Portfolio
7.4.1.3.1. NOVATM Newborn Genetic Test
7.4.1.3.1.1. Product Overview
7.4.1.3.1.2. Product Specifications and Test Methodology
7.4.1.3.2. NOVATM Metabolic Disease Screening
7.4.1.3.2.1. Product Overview
7.4.1.3.2.2. Product Specifications and Test Methodology
7.4.1.4. Future Outlook
7.4.2. Cordlife Group
7.4.2.1. Company Introduction
7.4.2.2. Financial Information
7.4.2.3. Product Portfolio
7.4.2.3.1. MetaScreenTM
7.4.2.3.1.1. Product Overview
7.4.2.3.1.2. Product Specifications and Test Methodology
7.4.2.4. Future Outlook
7.4.3. Genomi-k
7.4.3.1. Company Introduction
7.4.3.2. Product Portfolio
7.4.3.2.1. Audi-k® Service
7.4.3.2.1.1. Product Overview
7.4.3.2.1.2. Product Specifications and Test Methodology
7.4.3.2.2. Cardi-k® Service
7.4.3.2.2.1. Product Overview
7.4.3.2.2.2. Product Specifications and Test Methodology
7.4.3.2.3. Tami-k® Service
7.4.3.2.3.1. Product Overview
7.4.3.2.3.2. Product Specifications and Test Methodology
7.4.4. Genetadi Biotech
7.4.4.1. Company Introduction
7.4.4.2. Product Portfolio
7.4.4.2.1. Neonatal-One Plus
7.4.4.2.1.1. Product Overview
7.4.4.2.1.2. Product Specifications and Test Methodology
7.4.4.3. Future Outlook
7.4.5. NextlineTM Diagnostics
7.4.5.1. Company Introduction
7.4.5.2. Product Portfolio
7.4.5.2.1. BIRTHRIGHT
7.4.5.2.1.1. Product Overview
7.4.5.2.1.2. Product Specifications and Test Methodology
7.4.5.3. Future Outlook
7.4.6. Parabase Genomics
7.4.6.1. Company Introduction
7.4.6.2. Financial Information
7.4.6.3. Product Portfolio
7.4.6.3.1. NewbornDxTM Test
7.4.6.3.1.1. Product Overview
7.4.6.3.1.2. Product Specifications and Test Methodology
7.4.6.3.2. NewbornDxTM HL
7.4.6.3.2.1. Product Overview
7.4.6.3.2.2. Product Specifications and Test Methodology
7.4.6.4. Future Outlook
7.4.7. PerkinElmer® Genetics
7.4.7.1. Company Introduction
7.4.7.2. Financial Information
7.4.7.3. Product Portfolio
7.4.7.3.1. StepOne® Newborn Screening Panel
7.4.7.3.1.1. Product Overview
7.4.7.3.1.2. Product Specifications and Test Methodology
7.4.7.4. Future Outlook
7.4.8. SouthGenetics
7.4.8.1. Company Introduction
7.4.8.2. Product Portfolio
7.4.8.2.1. BabyGenesTM
7.4.8.2.1.1. Product Overview
7.4.8.2.1.2. Product Specifications and Test Methodology
7.4.8.3. Future Outlook
7.4.9. Other Prominent Players
7.4.9.1. AB SCIEX
7.4.9.2. Aegis Sciences
7.4.9.3. ARCHIMEDlife
7.4.9.4. Baby Genes
7.4.9.5. CENTOGENE
7.4.9.6. EGL Genetic Diagnostics
7.4.9.7. GeneTech
7.4.9.8. iLife Discoveries
7.4.9.9. Macrogen
7.4.9.10. MapmygenomeTM
7.4.9.11. Navigene Genetic Science
7.4.9.12. NeoGen Labs
7.4.9.13. Next Biosciences
7.4.9.14. NIMGenetics
7.4.9.15. Pediatrix Medical Group
7.4.9.16. PreventiNe Life Care
7.4.9.17. Synapse Diagnostics
7.4.9.18. Trivitron Healthcare
7.5. Newborn Screening Programs: Government Initiatives
7.5.1. Asia Pacific
7.5.2. Europe
7.5.3. Latin America
7.5.4. Middle East and North Africa (MENA)
7.5.5. North America
7.6. Newborn Screening: Future Outlook
 
8. OTHER ASSOCIATED TESTS AND SERVICES
8.1. Chapter Overview
8.2. Carrier Testing/Preconception Care
8.2.1. Carrier Testing/Preconception Care: An Overview
8.2.2. Carrier Testing/Preconception Care: Commercialized Tests
8.3. Preimplantation Genetic Diagnosis/Screening (PGD/PGS)
8.3.1. PGD/PGS: An Overview
8.3.2. PGD/PGS: Commercialized Tests
8.4. Genetic Counseling and Direct to Customer (DTC) Genetic Testing Services
 
9. RECENT COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. NIPT: Recent Collaborations
9.3.1. Recent Collaborations: Distribution by Year
9.3.2. Recent Collaborations: Distribution by Type of Model
9.3.3. Recent Collaborations: Most Active Companies
9.4. Newborn Screening: Recent Collaborations
9.4.1. Recent Collaborations: Distribution by Year
9.4.2. Recent Collaborations: Distribution by Type of Model
9.4.3. Recent Collaborations: Most Active Companies
 
10. NIPT AND NEWBORN SCREENING: MARKET SIZING AND FORECAST
10.1. Chapter Overview
10.2. NIPT: Scope and Forecast Methodology
10.3. NIPT: Forecast Assumptions
10.3.1. Patient Population
10.3.2. Price of Test
10.3.3. Adoption/Penetration Rate
10.4. NIPT: Forecast Projections, 2017-2027
10.4.1. NIPT Market, 2017-2027
10.4.2. NIPT Market: Distribution by Patient Risk Group
10.4.3. NIPT Market: Distribution by Geography
10.4.3.1. NIPT Market in North America
10.4.3.2. NIPT Market in Europe
10.4.3.3. NIPT Market in Asia
10.4.3.4. NIPT Market in Rest of the World
10.4.4. NIPT Market: Distribution by Indication
10.4.5. NIPT Market: Distribution by Stage of Pregnancy
10.4.6. NIPT Market: Distribution by Share of Individual NIPTs
10.5. Newborn Screening: Opportunity Analysis
 
11. CONCLUSION
11.1. Prenatal Testing and Newborn Screening Have Emerged as Popular Diagnostic Tools for Identification of Genetic Abnormalities in Fetuses and Newborns
11.2. Continuous Innovation has Led to the Development of NIPTs and Advanced Newborn Screening Tests
11.3. These Novel Screening Methods Cater to a Wide Spectrum of Disease Indications
11.4. The Interest has Steadily Risen with the Presence of Multiple Start-ups Across Different Geographies
11.5. The Growing Number of Partnerships are Indicative of a Lucrative Future Potential
11.6. Despite the Ethical Challenges in Developing Countries, the NIPT Market is Likely to Prosper Significantly in the Long Term
11.7. While the Newborn Screening Market is Still Evolving with Advanced Techniques, the NIPT Diagnostic Market is Already Witnessing an Accelerated Growth
 
12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. Jim Patterson, Vice President, Sales and Marketing North America, EvolveGene®
12.3. Osama Fikry, Metabolic and Diagnostic Head, NewBridge Pharmaceuticals
12.4. Silke Arndt, Medical Scientist and NGS Manager, Inqaba Biotec
 
13. SURVEY ANALYSIS
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Focus Area of the Company
13.4. Type of Lead Product(s)
13.5. Purpose of Lead Product(s)
13.6. Commercial Availability of Lead Product(s)
13.7. Likely Market Size
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Genetic Disorders: Categories
Figure 3.2 Chromosomal Abnormalities: Numerical and Structural Disorders
Figure 3.3 Genetic Disorders in Fetuses
Figure 3.4 Genetic Disorders in Newborns
Figure 3.5 Chromosomal Abnormalities: Distribution by Type
Figure 3.6 Common Causes of Deaths in Newborns
Figure 3.7 Genetic Tests in Prenatal and Neonatal Care
Figure 3.8 Genetic Testing: Benefits and Drawbacks
Figure 3.9 Reasons for Prenatal Testing
Figure 3.10 Evolution of Prenatal Testing
Figure 3.11 Conventional Prenatal Tests in Different Stages of Pregnancy
Figure 3.12 Maternal Serum Screening Tests: Available Options
Figure 3.13 Reasons to Perform Ultrasound at Various Stages in Pregnancy
Figure 3.14 Amniocentesis: General Procedure
Figure 3.15 Newborn Screening: Components
Figure 3.16 Newborn Screening: Key Milestones
Figure 4.1 NIPT: Distribution by Stage of Development
Figure 4.2 NIPT: Distribution by Technology Platforms
Figure 4.3 NIPT: Distribution by Type of Indication
Figure 4.4 NIPT: Distribution by Chromosomal Abnormalities
Figure 4.5 NIPT: Distribution by Sex Chromosomal Abnormalities
Figure 4.6 NIPT: Distribution by Microdeletion Syndromes
Figure 4.7 NIPT: Distribution by Stage of Pregnancy
Figure 4.8 NIPT: Distribution by Result Turnaround Time
Figure 4.9 Newborn Screening: Distribution by Screening Type
Figure 4.10 Newborn Screening: Distribution by Technology Platforms
Figure 4.11 Newborn Screening: Distribution by Type of Indication
Figure 4.12 Newborn Screening: Distribution by Period of Sample Collection After Birth
Figure 4.13 Newborn Screening: Distribution by Result Turnaround Time
Figure 5.1 NIPTs: Categorization by Heat Map Analysis
Figure 5.2 NIPTs: Geographical Distribution of Industry Players
Figure 5.3 Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
Figure 5.4 Newborn Screening Developer Landscape: Distribution by Company Size and Geography
Figure 6.1 NIPTs: Key Objectives
Figure 6.2 NIPT Tests: Launch Timeline
Figure 6.3 Harmony® Test: Steps of Operation
Figure 6.4 BGI: Product Portfolio
Figure 6.5 NIFTY® Test: Key Milestones
Figure 6.6 NIFTY® Test: Eligible Patient Population
Figure 6.7 NIFTY® Test: Steps of Operation
Figure 6.8 Natera®: Annual Revenues, 2013-Q1 2017 (USD Million)
Figure 6.9 Natera®: Product Portfolio
Figure 6.10 Panorama® Test: Eligible Patient Population
Figure 6.11 Panorama® Test: Steps of Operation
Figure 6.12 SequenomTM: Evolution of the NIPT Portfolio
Figure 6.13 SequenomTM: Annual Revenues, 2011-Q1 2016 (USD Million)
Figure 6.14 SequenomTM: Product Portfolio
Figure 6.15 Verifi® Prenatal Test: Eligible Patient Population
Figure 6.16 Verifi® Prenatal Test: Steps of Operation
Figure 7.1 Newborn Screening: Modes of Operation
Figure 7.2 NOVATM Newborn Genetic Test: Eligible Patient Population
Figure 7.3 NOVATM Newborn Genetic Test: Steps of Operation
Figure 7.4 Cordlife Group: Annual Revenues, 2012-2016 (USD Million)
Figure 7.5 Cordlife Group: Product Portfolio
Figure 7.6 Genomi-k: Product Portfolio
Figure 7.7 PerkinElmer®: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 7.8 Newborn Screening Programs: Current Geographical Spread
Figure 8.1 Carrier Testing: General Procedure
Figure 8.2 Carrier Testing: Recessive Disorders Inheritance
Figure 8.3 Carrier Testing: Clinical Benefits
Figure 8.4 Types of Predictive Testing
Figure 8.5 PGD: General Procedure
Figure 8.6 PGD: Most Common Types of Genetic Disorders
Figure 8.7 Purpose of Opting for Genetic Counseling
Figure 8.8 Reasons for Opting for Genetic Counseling
Figure 8.9 Essential Components of Genetic Counseling
Figure 8.10 Types of Genetic Counseling Services
Figure 9.1 Recent Collaborations in NIPT: Distribution by Year
Figure 9.2 Recent Collaborations in NIPT: Distribution by Type of Model
Figure 9.3 Recent Collaborations in NIPT: Most Active Players
Figure 9.4 Recent Collaborations in Newborn Screening: Distribution by Year
Figure 9.5 Recent Collaborations in Newborn Screening: Distribution by Type of Model
Figure 9.6 Recent Collaborations in Newborn Screening: Most Active Players
Figure 10.1 NIPT Market (2017-2027): Base Scenario (USD Billion)
Figure 10.2 NIPT Market (2017-2027): Distribution by Patient Risk Group, Base Scenario (USD Billion)
Figure 10.3 NIPT Market: Share by Patient Risk Groups, 2017, 2027 (USD Billion, %)
Figure 10.4 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (USD Billion)
Figure 10.5 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (Test Volume, Million)
Figure 10.6 NIPT Market: Share by Geography, 2017, 2027 (%)
Figure 10.7 NIPT Market in North America (2017-2027): Base Scenario (USD Billion)
Figure 10.8 NIPT Market in North America (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.9 NIPT Market in Europe (2017-2027): Base Scenario (USD Billion)
Figure 10.10 NIPT Market in Europe (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.11 NIPT Market in Asia (2017-2027): Base Scenario (USD Billion)
Figure 10.12 NIPT Market in Asia (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.13 NIPT Market in Rest of the World (2017-2027): Base Scenario (USD Billion)
Figure 10.14 NIPT Market in Rest of the World (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.15 NIPT Market: Share by Indication, 2017, 2027 (%)
Figure 10.16 NIPT Market: Share by Stage of Pregnancy, 2027 (%)
Figure 10.17 NIPT Market: Share by Individual NIPTs, 2017 (%)
Figure 11.1 Overall NIPT Market (USD Billion), 2017, 2022 and 2027
Figure 13.1 Survey Analysis: Distribution by Type of Company
Figure 13.2 Survey Analysis: Distribution by Location of Respondents
Figure 13.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 13.4 Survey Analysis: Distribution by Focus Area of the Company
Figure 13.5 Survey Analysis: Distribution by Type of Lead Products(s)
Figure 13.6 Survey Analysis: Distribution by Purpose of Lead Product(s)
Figure 13.7 Survey Analysis: Distribution by Commercial Availability of Lead Product(s)
Figure 13.8 Survey Analysis: Distribution by Likely Market Size of Prenatal Testing
Figure 13.9 Survey Analysis: Distribution by Likely Market Size of Newborn Screening

List of Tables

Table 3.1 Differences Between Screening and Diagnostic Tests
Table 3.2 Common Disorders: Annual Cost of Treatment
Table 3.3 Common Genetic Disorders: Causes and Symptoms
Table 3.4 Prenatal Testing: Invasive and Non-Invasive Methods
Table 3.5 Test Combinations in Triple and Quadruple Screen
Table 3.6 Triple Screen Assay: Abnormal Levels of Markers in Different Disorders
Table 3.7 Prenatal Screening Tests: Risk Assessment Strategies
Table 4.1 NIPTs: Development Landscape
Table 4.2 NIPT: Comparison of Sequencing based Technology Platforms
Table 4.3 NIPT: Technology Platforms
Table 4.4 Prenatal Testing: Other Initiatives
Table 4.5 Newborn Screening Tests: Development Landscape
Table 4.6 Newborn Screening: Other Initiatives
Table 5.1 NIPTs: Distribution by Geographical Coverage
Table 5.2 Heat Map Analysis: Scoring Criteria
Table 5.3 Commercialized NIPTs: A Competitive Heat Map Analysis
Table 5.4 Harvey Ball Analysis: Evaluation Criteria
Table 5.5 NIPT Harvey Ball Analysis: Distribution by Indications Screened Under Test Panel
Table 6.1 Ariosa Diagnostics: List of Funding Instances and Investors
Table 6.2 Harmony® Test: Launch Details for Different Geographies
Table 6.3 Harmony® Test: Published Studies
Table 6.4 Harmony® and Traditional Screening Methods: Comparison of Clinical Performance
Table 6.5 Harmony® Test: Comparison of Clinical Performance for Tested Indications
Table 6.6 Harmony® Test: Comparison of PPV in Different Patient Cohorts
Table 6.7 BGI: List of Funding Instances and Investors
Table 6.8 NIFTY® Test: Launch Details for Different Geographies
Table 6.9 Common NIPT Tests: Comparative Performance Evaluation
Table 6.10 NIFTY® and Traditional Screening Methods: Comparison of Clinical Performance
Table 6.11 NIFTY® Test: Published Studies
Table 6.12 NIFTY® Test: Comparison of Test Performance for the Tested Indications
Table 6.13 Natera®: List of Funding Instances and Investors
Table 6.14 Natera®: Summary of Marketed Products
Table 6.15 Panorama® Test: Launch Details for Different Geographies
Table 6.16 Panorama® Test: Available Options and Cost Details
Table 6.17 Panorama® Test: Comparison of PPV in Different Patient Cohorts
Table 6.18 Panorama® and Traditional Screening Methods: Comparison of Clinical Performance
Table 6.19 Panorama® Test: Comparison of Clinical Performance for Tested Indications
Table 6.20 Panorama® Test: Ongoing Clinical Trials
Table 6.21 SequenomTM NIPTs: Launch Details for Different Geographies
Table 6.22 SequenomTM: List of Funding Instances and Investors
Table 6.23 SequenomTM: Product Details
Table 6.24 MaterniT® GENOME Test: Comparison with Fetal Karyotype Test
Table 6.25 MaterniT® GENOME Test: Comparison of Clinical Performance for Tested Indications
Table 6.26 MaterniT® GENOME Test: Reasons for Increase in Clinical Uptake
Table 6.27 VisibiliTTM Test: Comparison of Clinical Performance for Tested Indications
Table 6.28 MaterniT21® PLUS Test: Published Studies
Table 6.29 NextViewTM Array Diagnostic Test Platform: Panel Options
Table 6.30 Illumina®: Regional Laboratory Partners for Verifi® Prenatal Test
Table 6.31 Verinata Health: List of Funding Instances and Investors
Table 6.32 Verifi® Prenatal Test: Launch Details for Different Geographies
Table 6.33 Verifi® Prenatal Test: Comparison of Clinical Performance for Tested Indications
Table 6.34 Popular NIPTs: A Detailed Comparision
Table 7.1 Traditional and Next-Generation Newborn Screening: Comparison
Table 7.2 Newborn Screening: List of Companies Profiled
Table 7.3 NOVATM Newborn Genetic Test: Clinical Performance Validation
Table 7.4 Cordlife Group: List of Funding Instances and Investors
Table 7.5 MetaScreenTM Testing Platforms: A Detailed Comparison
Table 7.6 MetaScreenTM: Available Options
Table 7.7 Parabase Genomics: List of Funding Instances and Investors
Table 7.8 PerkinElmer® Diagnostics Segment: Product Details
Table 7.9 PerkinElmer® Genetics: Available Products and Cost Details
Table 7.10 AB SCIEX: Company Profile
Table 7.11 Aegis Sciences: Company Profile
Table 7.12 ARCHIMEDlife: Company Profile
Table 7.13 Baby Genes: Company Profile
Table 7.14 CENTOGENE: Company Profile
Table 7.15 EGL Genetic Diagnostics: Company Profile
Table 7.16 GeneTech: Company Profile
Table 7.17 iLife Discoveries: Company Profile
Table 7.18 Macrogen: Company Profile
Table 7.19 MapmygenomeTM: Company Profile
Table 7.20 Navigene Genetic Science: Company Profile
Table 7.21 NeoGen Labs: Company Profile
Table 7.22 Next Biosciences: Company Profile
Table 7.23 NIMGenetics: Company Profile
Table 7.24 Pediatrix Medical Group: Company Profile
Table 7.25 PreventiNe Life Care: Company Profile
Table 7.26 Synapse Diagnostics: Company Profile
Table 7.27 Trivitron Healthcare: Company Profile
Table 7.28 Recommended Uniform Screening Panel (RUSP): Core and Secondary Disorders
Table 8.1 Carrier Testing: Most Prominent Disorders
Table 8.2 Carrier Testing/Preconception Care: Commercialized Tests
Table 8.3 PGD/PGS: Commercialized Tests
Table 9.1 NIPT: Recent Collaborations (2011-2017)
Table 9.2 Newborn Screening: Recent Collaborations (2011-2017)
Table 10.1 NIPT Forecast Assumptions: Patient Population
Table 10.2 NIPT Forecast Assumptions: Price Estimation
Table 10.3 NIPT Forecast Assumptions: Adoption Rates and Geographical Trends
Table 10.4 Newborn Screening: Opportunity Analysis, 2017-2027
Table 13.1 Survey Response: Overview of the Participating Companies
Table 13.2 Survey Response: Seniority Level of Respondents
Table 13.3 Survey Response: Focus Area of the Company
Table 13.4 Survey Response: Type of Lead Product(s)
Table 13.5 Survey Response: Purpose of Lead Product(s)
Table 13.6 Survey Response: Commercial Availability of Lead Product(s)
Table 13.7 Survey Response: Likely Market Size
Table 14.1 Chromosomal Abnormalities: Distribution by Type
Table 14.2 Common Causes of Deaths in Newborns
Table 14.3 NIPT: Distribution by Stage of Development
Table 14.4 NIPT: Distribution by Technology Platform
Table 14.5 NIPT: Distribution by Type of Indications
Table 14.6 NIPT: Distribution by Chromosomal Abnormalities
Table 14.7 NIPT: Distribution by Sex Chromosomal Abnormalities
Table 14.8 NIPT: Distribution by Microdeletion Syndromes
Table 14.9 NIPT: Distribution by Stage of Pregnancy
Table 14.10 NIPT: Distribution by Result Turnaround Time
Table 14.11 Newborn Screening: Distribution by Screening Type
Table 14.12 Newborn Screening: Distribution by Technology Platforms
Table 14.13 Newborn Screening: Distribution by Type of Indications
Table 14.14 Newborn Screening: Distribution by Screening Type on the Basis of Period of Sample Collection After Birth
Table 14.15 Newborn Screening: Distribution by Result Turnaround Time
Table 14.16 Natera®: Annual Revenues, 2013-Q1 2017 (USD Million)
Table 14.17 SequenomTM: Annual Revenues, 2011-Q1 2016 (USD Million)
Table 14.18 Cordlife Group: Annual Revenues, 2012-2016 (USD Million)
Table 14.19 PerkinElmer®: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.20 Recent Collaborations in NIPT: Distribution by Year
Table 14.21 Recent Collaborations in NIPT: Distribution by Type of Model
Table 14.22 Recent Collaborations in NIPT: Most Active Players
Table 14.23 Recent Collaborations in Newborn Screening: Distribution by Year
Table 14.24 Recent Collaborations in Newborn Screening: Distribution by Type of Model
Table 14.25 Recent Collaborations in Newborn Screening: Most Active Players
Table 14.26 NIPT Market: Distribution by Patient Population into Risk Groups
Table 14.27 NIPT Market (2017-2027): Base Scenario (USD Billion)
Table 14.28 NIPT Market (2017-2027): Optimistic Scenario (USD Billion)
Table 14.29 NIPT Market (2017-2027): Conservative Scenario (USD Billion)
Table 14.30 NIPT Market (2017-2027): Distribution by Patient Risk Group, Base Scenario (USD Billion)
Table 14.31 NIPT Market (2017-2027): Distribution by Patient Risk Group, Optimistic Scenario (USD Billion)
Table 14.32 NIPT Market (2017-2027): Distribution by Patient Risk Group, Conservative Scenario (USD Billion)
Table 14.33 NIPT Market: Share by Patient Risk Group, 2017, 2027 (USD Billion, %)
Table 14.34 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (USD Billion)
Table 14.35 NIPT Market (2017-2027): Distribution by Geography, Optimistic Scenario (USD Billion)
Table 14.36 NIPT Market (2017-2027): Distribution by Geography, Conservative Scenario (USD Billion)
Table 14.37 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (Test Volume, Million)
Table 14.38 NIPT Market (2017-2027): Distribution by Geography, Optimistic Scenario (Test Volume, Million)
Table 14.39 NIPT Market (2017-2027): Distribution by Geography, Conservative Scenario (Test Volume, Million)
Table 14.40 NIPT Market: Share by Geography, 2017, 2027 (%)
Table 14.41 NIPT Market in North America (2017-2027): Base Scenario (USD Billion)
Table 14.42 NIPT Market in North America (2017-2027): Optimistic Scenario (USD Billion)
Table 14.43 NIPT Market in North America (2017-2027): Conservative Scenario (USD Billion)
Table 14.44 NIPT Market in North America (2017-2027): Base Scenario (Test Volume, Million)
Table 14.45 NIPT Market in North America (2017-2027): Optimistic Scenario (Test Volume, Million)
Table 14.46 NIPT Market in North America (2017-2027): Conservative Scenario (Test Volume, Million)
Table 14.47 NIPT Market in Europe (2017-2027): Base Scenario (USD Billion)
Table 14.48 NIPT Market in Europe (2017-2027): Optimistic Scenario (USD Billion)
Table 14.49 NIPT Market in Europe (2017-2027): Conservative Scenario (USD Billion)
Table 14.50 NIPT Market in Europe (2017-2027): Base Scenario (Test Volume, Million)
Table 14.51 NIPT Market in Europe (2017-2027): Optimistic Scenario (Test Volume, Million)
Table 14.52 NIPT Market in Europe (2017-2027): Conservative Scenario (Test Volume, Million)
Table 14.53 NIPT Market in Asia (2017-2027): Base Scenario (USD Billion)
Table 14.54 NIPT Market in Asia (2017-2027): Optimistic Scenario (USD Billion)
Table 14.55 NIPT Market in Asia (2017-2027): Conservative Scenario (USD Billion)
Table 14.56 NIPT Market in Asia (2017-2027): Base Scenario (Test Volume, Million)
Table 14.57 NIPT Market in Asia (2017-2027): Optimistic Scenario (Test Volume, Million)
Table 14.58 NIPT Market in Asia (2017-2027): Conservative Scenario (Test Volume, Million)
Table 14.59 NIPT Market in Rest of the World (2017-2027): Base Scenario (USD Billion)
Table 14.60 NIPT Market in Rest of the World (2017-2027): Optimistic Scenario (USD Billion)
Table 14.61 NIPT Market in Rest of the World (2017-2027): Conservative Scenario (USD Billion)
Table 14.62 NIPT Market in Rest of the World (2017-2027): Base Scenario (Test Volume, Million)
Table 14.63 NIPT Market in Rest of the World (2017-2027): Optimistic Scenario (Test Volume, Million)
Table 14.64 NIPT Market in Rest of the World (2017-2027): Conservative Scenario (Test Volume, Million)
Table 14.65 NIPT Market: Share by Indication, 2017, 2027 (%)
Table 14.66 NIPT Market: Share by Stage of Pregnancy, 2017 (%)
Table 14.67 NIPT Market: Share by Individual NIPTs, 2017 (%)
Table 14.68 Overall NIPT Market Summary (USD Billion): 2017, 2022 and 2027
Table 14.69 Survey Analysis: Distribution by Type of Company
Table 14.70 Survey Analysis: Distribution by Location of Respondents
Table 14.71 Survey Analysis: Distribution by Seniority Level of Respondents
Table 14.72 Survey Analysis: Distribution by Focus Area of the Company
Table 14.73 Survey Analysis: Distribution by Lead Product(s)
Table 14.74 Survey Analysis: Distribution by Purpose of Lead Product(s)
Table 14.75 Survey Analysis: Distribution by Commercial Availability of Lead Product(s)
Table 14.76 Survey Analysis: Distribution by Likely Market Size of Prenatal Testing
Table 14.77 Survey Analysis: Distribution by Likely Market Size of Newborn Screening

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 23andMe
  • Cell Genetics
  • Genetadi Biotech
  • K3
  • NIPD Genetics
  • SeraCare Life Sciences
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct extensive secondary research as well as interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and sub-segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

Chapter Outlines

  • Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current state of the NIPT and the newborn screening market and its likely evolution over the next decade.
  • Chapter 3 provides a general introduction of various types of chromosomal abnormalities and genetic disorders occurring in fetuses and newborns with information on their statistics, and the different types of genetic tests available for their detection. It outlines the concept of invasive and non-invasive prenatal testing. In addition, the chapter offers a discussion on the historical evolution of newborn screening.
  • Chapter 4 provides a holistic view of the NIPT and newborn screening market. It provides a comprehensive list of NIPT and newborn screening tests. The chapter includes a detailed analysis of the NIPTs based on the development stage, technology platforms, type of indications tested, stage of pregnancy and result turnaround time. In addition, it includes a detailed analysis of the newborn screening tests based on the screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time. The chapter also lists the basic prenatal testing and newborn screening tests, devices, systems and technology platforms.
  • Chapter 5 is a compilation of key insights gained from this study. It includes a geographical coverage analysis that highlights the availability of each NIPT test in different regions across the globe, and a heat map representing the relative clinical performance of the commercially available NIPTs on the basis of sensitivity, specificity, result turnaround time and the stage of pregnancy when the test can be performed. In addition, it presents a Harvey ball analysis depicting the test panel strength on the basis of number of indications screened, and a world map to represent the geographical presence and the activity of companies involved in the field of NIPT. The chapter also includes a grid representation of the newborn screening tests, highlighting the distribution of these tests on the basis of screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and the technology platforms used to design them. Additionally, it features a developer landscape of the companies involved in the field of newborn screening, distributed on the basis of the company size and geographical presence.
  • Chapter 6 offers a comprehensive discussion on NIPT tests, highlighting advantages and challenges associated with the development and use of these tests. The chapter features detailed company profiles of the leading players that are involved in the development of NIPT tests. Each profile includes a brief overview of the company, its financial information, funding details, product portfolio and an informed future outlook. It also includes detailed profiles of the products of these key players. Each product profile provides information on the development history, specifications, technology platform, procedure, advantages and clinical information of different products offered by the company. In addition, the chapter includes a development timeline marking the launch of the popular NIPT tests between 2011 and 2016. It also provides a commercial landscape of the most popular NIPTs on the basis of different characteristics of these tests.
  • Chapter 7 offers a comprehensive discussion on newborn screening. It talks about different types of next-generation newborn screening procedures. We have provided company profiles and product profiles of the key players engaged in the development of newborn screening tests. In addition, it includes brief profiles of other players involved in this field. The section also includes an elaborate discussion on the current spread of newborn screening programs established in various countries across the globe to provide proper medical care to newborns.
  • Chapter 8 provides details on the other diagnostic tests / services available for genetic testing in newborns and fetuses; these include carrier testing / preconception care, preimplantation genetic testing (PGT) (preimplantation genetic diagnosis/screening (PGD / PGS)), genetic counselling and direct to consumer (DTC) genetic testing services. We have provided a brief overview of these tests / services, highlighting their general procedure / workflow, indications being evaluated and their indicative development pipeline.
  • Chapter 9 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in both NIPT and newborn screening markets. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain.
  • Chapter 10 highlights the market forecast and sizing of the overall NIPT and newborn screening markets. This chapter discusses, in detail, the parameters that are likely to influence the evolution of these markets. It features detailed insights on the likely evolution of the NIPT market for different patient risk group segments (high risk, average risk and low risk). The chapter highlights the likely distribution of the market across North America (US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia (Japan, China and India) and rest of the world. It also presents a detailed market segmentation by the key indications, stage of pregnancy when the tests can be performed and share of individual NIPT tests. In addition, the chapter offers a high-level view on the upcoming newborn screening market across the globe.
  • Chapter 11 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of both NIPT and newborn screening market based on the research and analysis described in the previous chapters.
  • Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in these fields.We have presented the insights provided to us by Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®),Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec).
  • Chapter 13 illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies involved in NIPT and / or newborn screening fields.
  • Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
  • Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.
Note: Product cover images may vary from those shown
5 of 5
  • 23andMe
  • A*STAR’s Institute of Microelectronics (IME)
  • AB SCIEX
  • Abbott Molecular
  • Abbott Pathology
  • Academy of Finland
  • Accela
  • Acibadem Healthcare Group
  • American College of Medical Genetics and Genomics (ACMG)
  • American Congress of Obstetrics and Gynecology (ACOG)
  • Adgenix
  • Advance Medical
  • Advanced Liquid Logic
  • Aegis Sciences
  • Aetna
  • Affymetrix
  • Agena Bioscience
  • Agilent Technologies
  • AL Borg Medical Laboratories
  • Alafi Capital
  • Alloy Ventures
  • Alpert Medical School, Brown University
  • Amarey Nova Medical Group
  • Amedes
  • American Association for Laboratory Accreditation (A2LA)
  • American Association of Blood Banks (AABB)
  • American Clinical Laboratory Association (ACLA)
  • American Medical Association (AMA)
  • American Hospital of Paris
  • Ani Biotech
  • Ani Labsystems
  • Annoroad Gene Technology
  • Anthem Blue Cross and Blue Shield
  • Antisel
  • APHL - Association of Public Health Laboratories
  • Applied Spectral Imaging (ASI)
  • Arabian Genetic Testing Company (AGTC)
  • ARCEDI Biotech
  • ARCHIMEDlife
  • Ariosa Diagnostics
  • ARUP Laboratories
  • Asia Pacific Capital Management
  • Asper Biotech
  • Astoria-Pacific
  • Atlas Genomics
  • Australian Clinical Lab
  • AutoGenomics
  • Baby Genes
  • Baebies
  • Bangkok Cytogenetics Center
  • Bangkok R.I.A LAB
  • Basetra
  • Baylor Genetics
  • BEAZ
  • Berry Genomics
  • BGI
  • BGI Agriculture
  • BGI College
  • BGI Diagnosis
  • BGI Forensics
  • BGI Genomics
  • BGI Health
  • BGI Manufacturing
  • BGI Research
  • BGI Tech
  • Big Belli
  • BioGen Medical
  • Biomnis
  • BioPoint
  • Bio-Rad Laboratories
  • BioReference Laboratories
  • Bioscience Genomics
  • Bioscience Institute
  • Birmingham Women’s Hospital
  • BlueGenome
  • Bome Sanayi Ürünleri Dis Ticaret
  • Brown University
  • CairoGene
  • California Department of Health
  • CAPP Medical
  • Catholic Health Initiatives (CHI)
  • Cell Genetics
  • CellScape
  • Cenata
  • Center for Human Genetics and Laboratory Diagnostics
  • Center for Medical Genetics, Houston
  • Center for Medical Genomics (CMG)
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare and Medicaid Services (CMS)
  • CENTOGENE
  • CENTOGENE ARABIA
  • Centrum Badan DNA Group
  • CGC Genetics
  • Children’s Mercy Hospital, Kansas
  • China National GeneBank
  • China’s National Health and Family Planning Commission
  • Chinese Food and Drug Administration
  • Cigna
  • Cinven
  • Claremont Creek Ventures
  • Clarity Medical Systems
  • CML Healthcare Collection Centers
  • CMS Computers
  • Coalition for Access to Prenatal Screening (CAPS)
  • College of American Pathologists (CAP)
  • Color Genomics
  • CombiMatrix
  • Commission for Office Laboratory Accreditation
  • Complete Genomics
  • Cooper SurgicalTM
  • CooperGenomics
  • Cordlife Group
  • Cordlife Sciences
  • Council of Regional Networks for Genetic Services
  • Counsyl
  • Cypher Genomics
  • Cyprus Institute of Neurology and Genetics
  • Cytogenomic External Quality Assessment Service (CEQAS)
  • DaAn Gene
  • Danaher Corporation
  • DASA Group
  • Datar Genetics
  • DBS Systems
  • deCODEme genetics
  • Department of Health and Human Services (HHS), US
  • Devyser
  • DiagCor
  • Diputación de Bizkaia
  • DNA Diagnostics Center (DDC)
  • Domain Associates
  • Dorevitch Pathology
  • Douglass Hanly Moir Pathology
  • Dr Lal PathLabs
  • DrGene
  • Eastern Biotech & Life Sciences
  • Echevarne
  • EGL Genetic Diagnostics
  • ELAN Group
  • ELIPS
  • Elite PharmaLab Solutions
  • Elucigene Diagnostics
  • Emory Genetic Diagnostics
  • Emory University's School of Medicine
  • Empireo Molecular Diagnostic
  • Eone Life Science Institute and Diagnomics
  • EONE-DIAGNOMICS Genome Center (EDGC)
  • ePlanet Ventures
  • ESPERITE
  • Eurofins Clinical Genetics India (ECGI)
  • Eurofins Scientific
  • European Diagnostics Services Group
  • European Molecular Genetics Quality Network (EMQN)
  • EvolveGene®
  • Famina Healthcare
  • FASTERIS
  • Food and Drug Administration (FDA)
  • Fetal Medicine Foundation
  • Fidelity Growth
  • Finnish Funding Agency for Innovations
  • Flatiron Health
  • Fleury Medicina e Saúde (Fleury Group)
  • Florida Agency for Health Care and Administration
  • Foundation for the Accreditation of Cellular Therapy (FACT)
  • Foundation Medicine
  • Founders Fund
  • Franklin Templeton Investments
  • Federal Trade Commission (FTC)
  • GATC Biotech
  • GENDIA (GENetic DIAgnostic Network)
  • Gene by Gene
  • GeneDx
  • GeneMetrics
  • Geneplus
  • GeneProof
  • Genesis GeneticsTM
  • Genesis GeneticsTM South Africa
  • GeneSupport
  • Genetadi Biotech
  • GeneTech
  • GeneTech Kazusa Laboratory
  • Genetic Associates
  • Genesis Genetics International
  • GeNext
  • Genia Technologies
  • GENNET
  • Genoks
  • GenoLogics Life Sciences Software
  • Genoma
  • Genomed
  • Genomic Diagnostics
  • Genomics For life
  • Genomi-k
  • Genomill Health
  • GenomixLAB
  • Genopharm
  • Genos
  • GenPath Diagnostics
  • Genpharm Services
  • Gentica
  • GENYCA
  • GigaScience
  • GN Otometrics
  • Good Start Genetics
  • Google India
  • GRAIL
  • GTL DNA
  • Harmony Partners
  • Headland Capital
  • Health Professional Council of South Africa (HPCSA)
  • Health Resources and Services Administration (HRSA)
  • HealthCor Partners
  • Helicos BioSciences
  • Helix Holdings
  • HemaXis
  • HemoFlux
  • Henry Schein Medical
  • Hitech Diagnostic Centre
  • Hive Technologies
  • Hologic
  • Hong Kong Molecular Pathology Diagnostic Centre
  • Hong Kong Screening Centre
  • Hospital Israelita Albert Einstein
  • Humana
  • IBL International
  • Icahn School of Medicine at Mount Sinai
  • Integrated Gulf Biosystems
  • iGene Diagnostics
  • IGENOMIX
  • Igentify
  • iLife Discoveries
  • Illumina®
  • IMUA Family Services
  • India Value Fund Advisors (IVFA)
  • Indian Department of Biotechnology
  • INEX (Innovations Exchange)
  • InKaryo
  • Innermost Healthcare
  • Innovation Elite
  • Inova Translational Medical Institute
  • Inqaba Biotec
  • Insight Medical Genetics
  • Institute of Medical Genetics, College of Life Science, Sichuan University
  • Integrated Genetics
  • Intercare Salubrity
  • International 22q11.2 Foundation
  • InterWest Health
  • Invitae
  • IQuum
  • Isis Innovation
  • International Society for Prenatal Diagnosis (ISPD)
  • Istenhegyi Centre for Genetic Diagnostics
  • IVF Michigan
  • IVIOMICS
  • Jennison Associates
  • Joaquim Chaves Group
  • Joint Commission on Accreditation of Healthcare Organizations
  • Just4Me Genetics
  • K3
  • Kalorama Information
  • Kansas City School of Medicine, University of Missouri
  • Kapa Biosystems and Signature Diagnostics
  • KellBenx
  • Knome
  • Knox Audiology
  • LABCO Quality Diagnostics
  • Laboratoire Cerba
  • Laboratory Corporation of America® Holding
  • LaboSud
  • Labsystems Diagnostics
  • Laverty Pathology
  • Li Ka Shing Institute of Health Sciences
  • Life TechnologiesTM
  • LifeCodexx
  • LifeGlobal Group
  • LifeLabs Genetics
  • Lightspeed Venture Partners
  • Lilac Insights
  • Macrogen
  • Magee-Women’s Hospital of UPMC Center for Medical Genetics
  • Mahidol University
  • MAICO Diagnostics
  • Malaysia Fetal Genome
  • MAP Diagnostics
  • Mapmygenome™
  • Maryland Department of Health and Mental Hygiene
  • Masimo® Corporation
  • Maternal and Child Health Bureau (MCHB)
  • Maverix Biomics
  • Mayo Medical Laboratories
  • McKesson Medical-Surgical
  • MedGen
  • MedGenome
  • Medical Chambers Kensington
  • Medical Genetics Laboratory, Baylor College of Medicine
  • Medical Genomics
  • Medisupport
  • MedLab Asia Group
  • MEDNAX
  • Meritech Capital Partners
  • Metis Genetics
  • Metropolis
  • Ministry of Science and Technology, India
  • MIT Angels
  • Mohr Davidow Ventures
  • Molecular Devices
  • Monobind
  • MOR Institute for Medical Data
  • Mount Sinai Genetic Testing Laboratory
  • MSA Safety
  • MultiCare
  • Multigene Diagnostics
  • MultiPlan
  • Multiplicom
  • Murdoch Children’s Research Institute
  • MyGenetx
  • MyMedLab
  • Myraqa
  • National Accreditation Board for Testing and Calibration Laboratories (NABL)
  • Natera®
  • National Health and Family Planning Commission (NHFPC)
  • National Institutes of Health (NIH)
  • National Newborn Bloodspot Screening Laboratory (NNBSL), Temple StreetChildren’s University Hospital
  • National Society of Genetic Counselors
  • National University of Singapore (NUS)
  • Natus® Medical
  • Navigene Genetic Science
  • NeoGen Labs
  • NEUROSPEC
  • New Born Solutions
  • New York Department of Health
  • New York State Laboratory
  • Newborn Foundation
  • NewBorn Gene ID
  • NewBridge Pharmaceuticals
  • Next Biosciences
  • NextBio
  • NextlineTM Diagnostics
  • NicView
  • NIMGenetics
  • NIPD Genetics
  • North-West University
  • Novogene
  • NX Prenatal
  • NxGen MDx
  • Onsite Neonatal Partners
  • OPKO Health
  • OrbiMed
  • Otometrics
  • Oxford Biosystems
  • Oxford Gene Technology (OGT)
  • OZ Systems
  • PacGenomics
  • Pacific Rim Pathology
  • Padtan
  • Paperboy Ventures
  • Parabase Genomics
  • Paragon Genomics
  • Pathology Associates Medical Laboratories (PAML)
  • Pathway Genomics
  • Pediatrix Medical Group
  • Pennsylvania Department of Health
  • Perinatal Quality Foundation (PQF)
  • PerkinElmer® Genetics
  • Personal Genomics
  • Phoebus Genetics
  • Pink Newborn Services
  • PlexBio
  • Positive Bioscience
  • Postnatal Peace
  • Pregnicare
  • Premaitha Health
  • Prenatal Diagnosis Centers (PDC)
  • Prenatal Genetics
  • Prenetics
  • Pressure BioSciences
  • PreventiNe Life Care
  • Previvo Genetics
  • Primary Health Care
  • Profema
  • Progenesis
  • Progenitest
  • Progenity
  • Pronto Diagnostics
  • ProPath
  • Providence Health & Services
  • QML Pathology
  • Quantum Diagnostics
  • Quest Diagnostics
  • RA Capital Management
  • Ramathibodi Hospital, Thailand
  • Rarecells
  • Ravgen
  • Recombine
  • Red Rock Fertility Center
  • Reproductive Genetic Innovations (RGI)
  • Reprogenetics
  • Rhode Island Department of Health
  • Roche
  • Rothschild Ventures Asia
  • S.R.L
  • Safembryo
  • Sagentia
  • Science Labs NIPT
  • ScreenCell
  • Sebia
  • Secretary's Advisory Committee on Heritable Disorders in Newborns and Children(SACHDNC)
  • Secuvita
  • Sengenics
  • Seoul National University Hospital (SNUH)
  • SequenomTM
  • Sequenom Center for Molecular Medicine (SCMM)
  • Sequoia Capital
  • SeraCare Life Sciences
  • Servicios Genéticos OriGen
  • Shenz Medical Center
  • Shenzhen BGI Unicare Clinic
  • Shenzhen Chi-Next Exchange
  • Shimadzu Corporation
  • Sichuan University
  • Siemens
  • Silicon Biosystems
  • Singapore Angel Network
  • Singlera Genomics
  • Siriraj Hospital, Thailand
  • Sistemas Genómicos
  • SNPgenomics
  • Sofinnova Ventures
  • SOFIVA Genomics
  • Solstas Lab Partners
  • Sonic Healthcare
  • Sophia Genetics
  • Source BioScience
  • SouthGenetics
  • SpOtOn Clinical Diagnostics
  • Srushti Hospital, India
  • St. George’s University
  • St. George's Hospital
  • Stanford University
  • StartUp Health
  • Sutter Hill Ventures
  • Swiss Institute for Bioinformatics
  • SXE Ventures
  • Synapse Diagnostics
  • SYNERGY Medical Systems
  • SYNLAB
  • Tasmanian Medical Laboratories
  • TATAA Biocenter
  • Teva Pharmaceutical
  • Thailand Center of Excellence for Life Sciences (TCELS)
  • The Chinese University of Hong Kong
  • The Doctors Laboratory (TDL)
  • The Fetal Medicine Centre, London
  • The Society for Maternal-Fetal Medicine (SMFM)
  • Thermo Fisher Scientific
  • This Is My
  • TMC Life Sciences
  • TOMA Advanced Biomedical Assays
  • Tor Vergata University, Rome
  • Translational Health Science Technology Institute (THSTI)
  • Trivitron Healthcare
  • TrovaGene
  • Tulip Diagnostics
  • Tute Genomics
  • UK Centre of Excellence
  • UK NEQAS
  • UNIConnect
  • Unilabs
  • United Overseas Bank Venture Management
  • UnitedHealthcare
  • University of Antwerp
  • University of California
  • University of Hong Kong
  • University of Rochester
  • University of Turku
  • University of Washington
  • Vanadis Diagnostics
  • Vantari Genetics
  • Venrock
  • Verinata Health
  • Victorian Clinical Genetics Services (VCGS)
  • Viollier
  • Virion-Serion
  • Visional Medical
  • Visunex Medical Systems
  • Vivosonic
  • Walnut Venture Associates
  • West Midlands Regional Genetics Laboratory
  • Western Diagnostic Pathology
  • Wolfson Institute of Preventive Medicine
  • Women and Infant's Hospital, Rhode Island
  • World Health Organization (WHO)
  • WuXi AppTec (WuXi Biologics)
  • Xcelom
  • Yale School of Medicine
  • Yale Women and Children’s Center
  • Yikon Genomics
  • Yourgene Bioscience
  • ZenTec
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll